Tue, Jan 27, 2015, 8:00 AM EST - U.S. Markets open in 1 hr 30 mins

Recent

% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • snogreen snogreen Jun 13, 2013 9:24 AM Flag

    From WebMD site

    "Epidermolysis bullosa (EB) is a genetic skin disorder characterized clinically by blister formation from mechanical trauma. There are three main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either mildly or severely affected. EB ranges from being a minor inconvenience requiring modification of some activities, to being completely disabling and, in some cases, fatal.

    "Currently, there is no cure for EB. Supportive care includes daily wound care, bandaging, and pain management as needed."

    This is real big for RGRX. 8 of 22 completely healed, and I assume some were partially healed(?) And of the 8 of 22 healed, we don't know if they were on what of three groups - 0.01% dose, 0,03% dose or 0.1% dose. I assume the higher doses did best. This is the key sentance from WebMD:

    "Currently, there is no cure for EB. Supportive care includes daily wound care, bandaging, and pain management as needed."

    If RGRX can somehow explain to us and the FDA how the water gel placebo got a healing response, when all know a water gel won't work.....then we have a big win here. And RGRX said they would keep the EB rights of TB 4 themselves and not partner it out - because the EB patients and Doctors are easliy found in the worldwide EB registry, to market it to. It is a $200-$300 million annual market. Right now all rests on RGRX somehow explaining to FDA how (??) placebo got a response. It might put the TB4 arm in question. But how can the FDA turn it down, if TB 4 did what there is: ""Currently, there is no cure for EB."

 
RGRX
0.15+0.01(+7.14%)Jan 26 9:30 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.